Cagrilintide 5mg
$80,00
people are viewing this right now
Cagrilintide is a long-acting, acylated amylin analog peptide developed for weight management and obesity treatment.
It mimics the hormone amylin, reducing appetite, enhancing satiety, and slowing gastric emptying. Clinical trials suggest significant weight loss, particularly when combined with the GLP-1 receptor agonist semaglutide (CagriSema)
Research use only. Not for human or veterinary use.
Guaranteed Checkout
-
Australia Wide Shipping
-
Delivers in: 3-7 Working Days Shipping & Return
Key Aspects of Cagrilintide:
- Mechanism of Action: As a long-acting amylin receptor agonist, it acts on the brain to reduce calorie intake and food cravings.
- Weight Loss Potential: In studies, it demonstrated significant efficacy alone and as a combination therapy.
- Combination Therapy (CagriSema): Cagrilintide is often paired with Semaglutide (creating “CagriSema”) for enhanced weight loss, aiming for greater reduction than existing GLP-1s alone.
- Administration: It is designed to be a once-weekly injection.
- Side Effects: Similar to other weight loss treatments, side effects may include mild injection site reactions, and potentially, gastrointestinal issues.
- Clinical Trials: Currently in late-stage Phase 3 trials (such as the REDEFINE program) to evaluate its long-term safety and efficacy.
- Dosage: Reconstitute with 2ml Bac water, starting dose 10 units subcutaneous injection once a week.
Cagrilintide represents a promising next-generation weight-loss strategy that operates via a different pathway than traditional GLP-1 drugs.
Research Use Only: Not for human or veterinary use.
| Strength | 5 mg, 10 mg |
|---|---|
| Pack size | 1 vial, 2 vials, 3 vials |
You may also like…
Hot
Related Products
Recently Viewed Products
